← 홈

전체 프로그램

ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-11 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 1,486개
AntibodystaleBeiGenePhase 2

Tislelizumab Combined With Bevacizumab and Platinum Plus Pemetrexed (Tislelizumab Combined With Bevacizumab and Platinum Plus Pemetrexed)

Non-squamous Non-small Cell Lung Cancer; EGFR Gene Mutation · EGFR

#EGFR#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 ACTIVE
AntibodystaleBeiGenePhase 2

Tislelizumab combined with chemotherapy (Tislelizumab combined with chemotherapy)

Rectal Cancer; Rectal Cancer Stage II · Rectal Cancer

#RectalCancer#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleBeiGenePhase 1

trastuzumab (Herceptin, Tislelizumab，atezolizumab or Trastuzumab)

Gastric Cancer · Gastric Cancer

#GastricCancer#Antibody#Phase1#항체#면역항체+2
임상시험 1상태 ACTIVE
CGTBiologicstaleUniversity of PennsylvaniaPhase 1

TmPSMA-02 CAR T Cells (TmPSMA-02 CAR T Cells)

Metastatic Castrate-Resistant Prostate Cancer (mCRPC) · PSMA

#PSMA#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 1상태 RECRUITING
AntibodystaleJunshi BiosciencesPhase 2

Toripalimab （12weeks） (Toripalimab （12weeks）)

Breast Cancer · Breast Cancer

#BreastCancer#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleJunshi BiosciencesPhase 2

Toripalimab （18weeks） (Toripalimab （18weeks）)

Breast Cancer · Breast Cancer

#BreastCancer#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleNorthwestern UniversityPhase 1

Transferrin Receptor-Targeted Liposomal p53 cDNA (Transferrin Receptor-Targeted Liposomal p53 cDNA)

Anatomic Stage IV Breast Cancer AJCC v8; Breast Inflammatory Carcinoma · Anatomic Stage IV Breast Cancer AJCC v8

#AnatomicStageIVBreastCancerAJCCv#Antibody#Phase1#항체#면역항체+3
임상시험 1상태 DISCONTINUED
AntibodystaleRochePreclinical

neoadjuvant (Trastuzumab, Trastuzumab (neoadjuvant))

HER2-positive Breast Cancer; Neoplasms · HER2

#HER2#Antibody#Preclinical#항체#면역항체+4
임상시험 1상태 ACTIVE
AntibodystaleRochePhase 2

trastuzumab (Herceptin, Trastuzumab + NK cells)

Breast Cancer; Gastric Cancer · Gastric Cancer

#GastricCancer#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 ACTIVE
AntibodystaleRochePhase 2

trastuzumab (Herceptin, Trastuzumab + Paclitaxel)

HER2-positive Breast Cancer; Operable Breast Cancer · HER2

#HER2#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 RECRUITING
AntibodystaleRochePhase 2

trastuzumab (Herceptin, Trastuzumab + Ramucirumab + Paclitaxel)

Recurrent/Metastatic Gastric Cancer · Recurrent/Metastatic Gastric Cancer

#RecurrentMetastaticGastricCancer#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 ACTIVE
AntibodystaleRochePhase 2

trastuzumab (Herceptin, Trastuzumab +Cetuximab β+Irinotecan)

HER2 Positive; Colorectal Cancer (CRC) · HER2

#HER2#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 RECRUITING
AntibodystaleRochePhase 2

trastuzumab (Herceptin, Trastuzumab - intravenous solution)

Breast Cancer · Breast Cancer

#BreastCancer#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 DISCONTINUED
AntibodystaleRochePhase 2

trastuzumab (Herceptin, Trastuzumab Biosimilar ABP 980)

Breast Cancer · Breast Cancer

#BreastCancer#Antibody#Phase2#항체#면역항체+2
효능 ORR 79.4%임상시험 1상태 ACTIVE
ADCBiologicstaleDaiichi SankyoPhase 2

trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201, Trastuzumab Deruxtecan and ivonescimab)

Breast Cancer · Breast Cancer

#BreastCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
임상시험 1상태 RECRUITING
AntibodystaleRochePhase 2

trastuzumab (Herceptin, Trastuzumab Pyrotinib Exemestane Dalpiciclib)

Breast Cancer; Estrogen Receptor Positive Tumor · HER2

#HER2#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 ACTIVE
AntibodystaleRochePhase 2

trastuzumab (Herceptin, Trastuzumab QW, Trastuzumab Q3W)

Breast Cancer · Breast Cancer

#BreastCancer#Antibody#Phase2#항체#면역항체+2
효능 ORR 9.5%임상시험 1상태 ACTIVE
AntibodystaleRochePhase 2

trastuzumab (Herceptin, Trastuzumab Rezetecan Combined with Adebelizumab)

Muscle-Invasive Bladder Cancer (MIBC) · Muscle-Invasive Bladder Cancer (MIBC)

#Muscle-InvasiveBladderCancerMIBC#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleRochePhase 2

trastuzumab (Herceptin, Trastuzumab and Pyrotinib)

Advanced Breast Cancer · Advanced Breast Cancer

#AdvancedBreastCancer#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleRochePhase 1

trastuzumab (Herceptin, Trastuzumab and non-pegylated liposomal doxorubicin)

Breast Cancer · Breast Cancer

#BreastCancer#Antibody#Phase1#항체#면역항체+2
효능 ORR 33.3%임상시험 1상태 ACTIVE

66 / 75 페이지

← 이전다음 →